SLC6A3 and Alzheimer disease: Dopaminergic FC differences, assessed using PET atlases of the dopamine transporter (DAT) and the dopaminergic receptor D1, show variability across the Alzheimer’s disease continuum, suggesting stage-specific involvement in the dopaminergic pathway.